Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters
US6555544B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | May 2, 2000 |
| Grant date | Apr 29, 2003 |
| Priority date | — |
| Expiry date | May 2, 2020 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S977/926
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is concerned with a pharmaceutical composition suitable as a depot formulation for administration via intramuscular or subcutaneous injection, comprising:(1) as an active ingredient a therapeutically effective amount of a 9-hydroxy-risperidone fatty acid ester or a salt, or a stereoisomer or a stereoisomeric mixture thereof in submicron form and(2) a pharmaceutically acceptable carrier; wherein the pharmaceutically acceptable carrier is water and the active ingredient is suspended therein:and with a process of preparing such a composition.The invention further concerns such a pharmaceutical composition for use as a medicament in the treatment of psychosis, schizophrenia, schizoaffective disorders, non-schizophrenic psychoses, behavioural disturbances associated with neurodegenerative disorders, e.g. in dementia, behavioural disturbances in mental retardation and autism, Tourette's syndrome, bipolar mania, depression, anxiety.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.